Skip to main content
Log in

Antiepileptic Drugs and Neurodevelopment: An Update

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

In utero exposure to some antiepileptic drugs (AEDs) is associated with an increased risk of impaired cognitive development. Specifically, valproate and polytherapy exposure are each associated with an increased risk of cognitive impairment in children compared with other antiepileptic medications. The data regarding the risk to neurocognitive development imposed by maternal use of other AEDs are conflicting or insufficient at this time to draw definitive conclusions. Behavioral dysfunction including autistic spectrum disorder is also associated with maternal use of AEDs during pregnancy. Whether treatment with AEDs during childhood permanently affects cognitive neurodevelopment is yet to be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet. 1968;292:1296.

    Article  Google Scholar 

  2. Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81:1–13.

    Article  PubMed  Google Scholar 

  3. Hill RM, Verniaud WM, Horning MG, et al. Infants exposed in utero to antiepileptic drugs. Am J Dis Child. 1974;127:645–53.

    PubMed  CAS  Google Scholar 

  4. Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr. 1976;89:662–8.

    Article  PubMed  CAS  Google Scholar 

  5. Leavitt AM, Yerby MS, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology. 1992;42 suppl 5:141–3.

    PubMed  CAS  Google Scholar 

  6. Losche G, Steinhausen, Koch S, et al. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994;83:961–6.

    Article  PubMed  CAS  Google Scholar 

  7. Granstrom ML, Gaily E. Psychomotor development in children of mothers with epilepsy. Neurology. 1992;42:144–8.

    PubMed  CAS  Google Scholar 

  8. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA. 1995;274:1518–25.

    Article  PubMed  CAS  Google Scholar 

  9. Majewski F, Steger M, Richter B, et al. The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Int J Biol Res Pregnancy. 1981;2:37–45.

    PubMed  CAS  Google Scholar 

  10. Wide K, Henning E, Tomson T, et al. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr. 2002;91:409–14.

    Article  PubMed  CAS  Google Scholar 

  11. Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999;40:1237–43.

    Article  PubMed  CAS  Google Scholar 

  12. • Nicolai J, Vles JSH, Aldenkamp AP. Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: a critical review directed at structural study-bias. J Neurol Sci. 2008;271:1–14. In this literature review, studies of the cognitive effects of in utero exposure are summarized and critically reviewed. Methodologies that should limit interpretation of study results are highlighted.

    Article  PubMed  CAS  Google Scholar 

  13. Adab N, Tudur Smith C, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy (Review). Cochrane Database of Systematic Reviews 2010, Issue 1.

  14. •• Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. NEJM. 2009;360:1597–605. This is the first prospective study of the long-term cognitive effects of in utero exposure to AEDs. It is also one of the few studies of this subject that analyzes factors that could confound the data.

    Article  PubMed  CAS  Google Scholar 

  15. Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51:2058–65.

    Article  PubMed  Google Scholar 

  16. Gaily E, Kantola-Sorsa MA, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004;62:28–32.

    PubMed  CAS  Google Scholar 

  17. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75:1575–83.

    Article  PubMed  CAS  Google Scholar 

  18. Thomas SV, Ajaykumar B, Sindhu K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008;13:229–36.

    Article  PubMed  Google Scholar 

  19. Titze K, Koch S, Helge H, et al. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev Med Child Neurol. 2008;50:117–22.

    Article  PubMed  Google Scholar 

  20. •• Vinten J, Bromley RL, Taylor J, et al. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009;14:197–2001. This study examines long-term behavior consequences of in utero exposure to AEDs. The cognitive tools used are scales that evaluate life skills and parental stress.

    Article  PubMed  CAS  Google Scholar 

  21. Dean JCS, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002;39:251–9.

    Article  PubMed  CAS  Google Scholar 

  22. Viinikainen K, Eriksson K, Monkkonen A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006;9:636–40.

    Article  PubMed  Google Scholar 

  23. Rasalam AD, Hailey H, Williams JHG, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol. 2005;47:551–5.

    Article  PubMed  CAS  Google Scholar 

  24. Bromley RL, Mawer G, Clayton-Smith J, et al. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008;71:1923–4.

    Article  PubMed  CAS  Google Scholar 

  25. Stefovska VG, Uckermann O, Czuczwar M, et al. Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol. 2008;64:434–45.

    Article  PubMed  Google Scholar 

  26. Manent JB, Jorquera I, Mazzucchelli I, et al. Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia. 2007;48:684–93.

    Article  PubMed  CAS  Google Scholar 

  27. Ogura H, Yasuda M, Nakamura S, et al. Neurotoxic damage of granule cells in the dentate gyrus and the cerebellum and cognitive deficit following neonatal administration of phenytoin in mice. J Neuropathol Exp Neurol. 2002;61:956–67.

    PubMed  CAS  Google Scholar 

  28. Wong WT, Wong RO. Changing specificity of neurotransmitter regulation of rapid dendritic remodeling during synaptogenesis. Nat Neurosci. 2001;4:351–2.

    Article  PubMed  CAS  Google Scholar 

  29. Bittagau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci. 2003;993:103–14.

    Article  Google Scholar 

  30. Katz I, Kim J, Gale KN, et al. Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J Pharmacol Exp Ther. 2007;322:494–500.

    Article  PubMed  CAS  Google Scholar 

  31. Kim J, Kondratyev A, Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy vs polytherapy. J Pharmacol Exp Ther. 2007;323:165–73.

    Article  PubMed  CAS  Google Scholar 

  32. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. NEJM. 1990;322:364–9.

    Article  PubMed  CAS  Google Scholar 

  33. Vining EPG, Mellits ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80:165–74.

    PubMed  CAS  Google Scholar 

  34. Calandre EP, Dominguez-Granados R, Gomez-Rubio M, et al. Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurol Scand. 1990;81:504–6.

    Article  PubMed  CAS  Google Scholar 

  35. Stores G, Hart J. Reading skills of children with generalized or focal epilepsy attending ordinary school. Dev Med Child Neurol. 1976;18:705–16.

    Article  Google Scholar 

  36. Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol. 1991;33:524–43.

    Article  PubMed  CAS  Google Scholar 

  37. Aman WG, Werry JS, Paxton JW, et al. Effects of carbamazepine on psychomotor performance in children as a function of dose, concentration, seizure type, and time of medication. Epilepsia. 1990;31:51–60.

    Article  PubMed  CAS  Google Scholar 

  38. Bailet LL, Turk WR. The impact of childhood epilepsy on neurocognitive and behavioral performance. Epilepsia. 2000;41:426–31.

    Article  PubMed  CAS  Google Scholar 

  39. Donati F, Gobbi G, Campistol J, et al. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure. 2007;16:670–9.

    Article  PubMed  Google Scholar 

  40. Pressler RM, Binnie CD, Coleshill SG, et al. Effect of lamotrigine on cognition in children with epilepsy. Neurology. 2006;66:1495–9.

    Article  PubMed  CAS  Google Scholar 

  41. Mandelbaum DE, Bunch M, Kugler SL, et al. Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug us. J Child Neurol. 2005;20:590–4.

    PubMed  Google Scholar 

  42. Levisohn PM, Mintz M, Hunter SJ, et al. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia. 2009;50:2377–89.

    Article  PubMed  CAS  Google Scholar 

  43. Kang H-C, Eun B-L, Lee CW, et al. The effects of cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with Benign Rolandic Epilepsy. Epilepsia. 2007;48:1716–23.

    Article  PubMed  CAS  Google Scholar 

  44. Coppola G, Verrotti A, Resicato G, et al. Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav. 2008;12:253–6.

    Article  PubMed  Google Scholar 

  45. Aarsen FK, van den Akker ELT, Drop SLS, et al. Effect of topiramate on cognition in obese children. Neurology. 2006;67:1307–8.

    Article  PubMed  Google Scholar 

  46. Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr. 1999;38:387–95.

    Article  CAS  Google Scholar 

  47. Vazquez B, Gibson P, Kustra R. Epilepsy and women’s health issues: unmet needs-survey results from women with epilepsy. Epilepsy Behav. 2007;10:163–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

K.J. Meador has received a grant from the National Institutes of Health (NIH); has been a consultant on grants for NIH; has been a Primary Investigator for a grant from NIH/National Institute of Neurological Disorders and Stroke; has been a Co-investigator on a grant from NIH/National Center on Minority Health and Health Disparities; and has been a Co-investigator on a grant from NIH.

Disclosure

Conflicts of interest: S. Palac: none; K.J. Meador: has been a Co-investigator on a grant from Epilepsy Foundation of America; has been a Primary Investigator for a grant from Pfizer Pharmaceuticals; has been a Primary Investigator and Co-investigator for grants from UCB Pharma; has been a Co-investigator on grants from Neuropace, Inc.; has been a Primary Investigator for a grant from GlaxoSmithKline; has been a Primary Investigator for a grant from Schwartz Biosciences (UCB Pharma); has been a Co-investigator on a grant from Marinus Pharmaceuticals, Inc.; has been a Co-investigator on a grant from Myriad Pharmaceuticals, Inc.; has traveled to speak for Sanofi Aventis; is on the editorial board for the journal Epilepsy Currents; and is a member of the professional advisory board for the Epilepsy Foundation of America.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Susan Palac.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palac, S., Meador, K.J. Antiepileptic Drugs and Neurodevelopment: An Update. Curr Neurol Neurosci Rep 11, 423–427 (2011). https://doi.org/10.1007/s11910-011-0194-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-011-0194-y

Keywords

Navigation